McKesson (NYSE:MCK) Releases FY25 Earnings Guidance

McKesson (NYSE:MCK - Get Free Report) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $32.40-33.00 for the period, compared to the consensus earnings per share estimate of $32.68. McKesson also updated its FY 2025 guidance to 32.400-33.000 EPS.

Analysts Set New Price Targets

A number of research firms have issued reports on MCK. Morgan Stanley boosted their price target on McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft cut their target price on shares of McKesson from $623.00 to $579.00 and set a "buy" rating for the company in a research report on Wednesday, September 25th. Leerink Partners dropped their price target on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Bank of America reduced their price objective on McKesson from $680.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, January 6th. Finally, Wells Fargo & Company lifted their target price on McKesson from $535.00 to $641.00 and gave the company an "equal weight" rating in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $646.14.

McKesson Stock Performance

Shares of McKesson stock traded down $10.22 on Wednesday, hitting $583.51. 566,241 shares of the company traded hands, compared to its average volume of 622,054. The business has a 50-day simple moving average of $595.09 and a 200 day simple moving average of $560.90. McKesson has a 52 week low of $464.42 and a 52 week high of $637.51. The stock has a market capitalization of $74.07 billion, a P/E ratio of 30.22, a price-to-earnings-growth ratio of 1.25 and a beta of 0.52.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping the consensus estimate of $6.88 by $0.19. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The business had revenue of $93.65 billion for the quarter, compared to analysts' expectations of $89.33 billion. During the same quarter in the previous year, the company earned $6.23 EPS. The business's quarterly revenue was up 21.3% compared to the same quarter last year. Research analysts expect that McKesson will post 32.73 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd were issued a dividend of $0.71 per share. The ex-dividend date was Monday, December 2nd. This represents a $2.84 annualized dividend and a dividend yield of 0.49%. McKesson's dividend payout ratio (DPR) is 14.71%.

Insider Activity

In related news, EVP Leann B. Smith sold 579 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $602.81, for a total value of $349,026.99. Following the completion of the transaction, the executive vice president now owns 1,443 shares of the company's stock, valued at approximately $869,854.83. This trade represents a 28.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.11% of the company's stock.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.